NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $0.02 0.00 (-8.05%) Closing price 11/10/2026Extended Trading$0.02 0.00 (0.00%) As of 11/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Karyopharm Therapeutics Stock (NASDAQ:KPTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get KPTI alerts:Sign Up Key Stats Today's Range$0.02▼$0.0350-Day Range$0.02▼$1.8852-Week Range$0.02▼$10.99Volume121.84 million shsAverage Volume24.32 million shsMarket Capitalization$362.88 thousandP/E RatioN/ADividend YieldN/APrice Target$11.50Consensus RatingHold Company Overview Karyopharm Therapeutics is a biopharmaceutical company focused on developing treatments for cancer. Founded in 2008 and headquartered in Newton, Massachusetts, the company’s research centers on blocking nuclear export, a process that can help cancer cells survive and grow. Its lead product is selinexor, marketed in the United States as Xpovio. The oral therapy is approved for certain adults with multiple myeloma, including use in combination with other medicines. Karyopharm is also developing selinexor and other drug candidates for additional cancers. Karyopharm’s commercial and development activities extend beyond the United States through international partnerships. Its clinical research has included blood cancers and solid tumors, with the aim of addressing treatment needs across a range of cancer types.AI Generated. May Contain Errors. Read More Karyopharm Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreKPTI MarketRank™: 2.505000666755 of 5 starsKaryopharm Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingKaryopharm Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialKaryopharm Therapeutics has a consensus price target of $11.50, representing about 71,775.0% upside from its current price of $0.02.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($4.05) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted36.92% of the float of Karyopharm Therapeutics has been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 13.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentKaryopharm Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Karyopharm Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,116.00 in company stock.Percentage Held by Insiders1.68% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KPTI Stock News HeadlinesKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Stock Has Average Price Target of $11.503 hours ago | americanbankingnews.comKaryopharm Therapeutics Inc. Announces FDA Acceptance Of Supplemental New Drug Application For XPOVIO Plus Ruxolitinib For The Treatment Of Patients With MyelofibrosisNovember 17 at 12:19 PM | marketscreener.comMA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.November 18 at 1:00 AM | Profits Run (Ad)Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with MyelofibrosisNovember 17 at 7:30 AM | prnewswire.comKaryopharm Therapeutics Reports Delay Amid Chapter 11 ProceedingsNovember 13, 2026 | tipranks.comKaryopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)November 4, 2026 | prnewswire.comKaryopharm files bankruptcy, to merge with AyrmidNovember 3, 2026 | msn.comKaryopharm Therapeutics Files for Chapter 11 Bankruptcy and Agrees to Planned Merger with AyrmidNovember 3, 2026 | finance.yahoo.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $7.36 on January 1st, 2026. Since then, KPTI shares have decreased by 99.8% and is now trading at $0.0160. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its earnings results on Thursday, August, 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by $0.95. The business had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million. Read the conference call transcript. When did Karyopharm Therapeutics' stock split? Karyopharm Therapeutics shares reverse split on Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Karyopharm Therapeutics IPO? Karyopharm Therapeutics (KPTI) raised $102 million in an initial public offering (IPO) on Wednesday, November 6th 2013. The company issued 6,800,000 shares at $14.00-$16.00 per share. Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' top institutional shareholders include Context Capital Management LLC (1.16%) and Goldman Sachs Group Inc. (1.13%). Insiders that own company stock include Stuart Poulton, Richard A Paulson, Reshma Rangwala, Sohanya Roshan Cheng, Michael Mason, Michael Mano and Kristin Abate. View institutional ownership trends. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Alibaba Group (BABA), Tesla (TSLA), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Pfizer (PFE). Company Calendar Last Earnings8/13/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, KPTI's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:KPTI CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees380Year Founded2008Price Target and Rating Average Price Target for Karyopharm Therapeutics$11.50 High Price Target$28.00 Low Price Target$3.00 Potential Upside/Downside+71,775.0%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($13.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.04 million Net Margins-153.28% Pretax Margin-153.30% Return on EquityN/A Return on Assets-145.18% Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.76 Sales & Book Value Annual Sales$146.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($16.00) per share Price / Book0.00Miscellaneous Outstanding Shares22,680,000Free Float22,300,000Market Cap$362.88 thousand OptionableOptionable Beta1.16 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:KPTI) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredAmerica's Biggest Bank… Down?About 4,800 Chase customers reported problems in just 15 minutes on Monday. Many couldn't log in or move money...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.